Disease-modifying drugs for multiple sclerosis must be globally available according to therapeutic guidelines suitable to different regions of the world.
Maria José
MJ
Sá
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000465:Algorithms; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents